Comparing the effectiveness of different EGFR‐TKIs in patients with EGFR mutant non–small‐cell lung cancer: a retrospective cohort study in Taiwan
YY Hsieh, WT Fang, YW Lo, YH Chen… - International journal of …, 2020 - Wiley Online Library
The study was to compare the effectiveness of different epidermal growth factor receptor—
tyrosine kinase inhibitors (EGFR‐TKIs) in patients with advanced non‐small‐cell lung …
tyrosine kinase inhibitors (EGFR‐TKIs) in patients with advanced non‐small‐cell lung …
Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with …
B Chua, EH Tan, DWT Lim, MK Ang… - Annals of …, 2018 - annalsofoncology.org
Background: Treatment options for EGFR mutant advanced/metastatic NSCLC patients
continue to evolve with the development of 2nd and 3rd generation EGFR TKIs. We aim to …
continue to evolve with the development of 2nd and 3rd generation EGFR TKIs. We aim to …
Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
JWC Chang, CY Huang, YF Fang, CF Chang… - Thoracic …, 2023 - Wiley Online Library
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
[HTML][HTML] The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
Therapeutic efficacy comparison of 5 major EGFR-TKIs in advanced EGFR-positive Non–Small-cell lung cancer: a network meta-analysis based on head-to-head …
Y Zhang, Z Zhang, X Huang, S Kang, G Chen, M Wu… - Clinical Lung Cancer, 2017 - Elsevier
Background Five major first-and second-generation epidermal growth factor receptor-
tyrosine kinase inhibitors (EGFR-TKIs), including erlotinib, gefitinib, icotinib, afatinib, and …
tyrosine kinase inhibitors (EGFR-TKIs), including erlotinib, gefitinib, icotinib, afatinib, and …
[HTML][HTML] Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort
I Okamoto, S Morita, N Tashiro, F Imamura, A Inoue… - Lung Cancer, 2018 - Elsevier
Objectives Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have
been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung …
been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung …
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a …
N Zhao, X Zhang, H Yan, J Yang, Y Wu - Lung Cancer, 2014 - Elsevier
Background EGFR mutation status is closely related to the efficacy of EGFR-TKIs in
advanced non-small cell lung cancer (NSCLC). EGFR-TKIs have become the standard first …
advanced non-small cell lung cancer (NSCLC). EGFR-TKIs have become the standard first …
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - Elsevier
Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
M Kanazu, M Mori, M Kimura, K Nishino… - Thoracic …, 2021 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy
is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring …
is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring …
[HTML][HTML] Meta-analysis of first-line therapies in advanced non–small-cell lung cancer harboring EGFR-activating mutations
Introduction: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …